@article{10.37349/etat.2024.00236,
abstract = {Background: This article is based on our previous research, which was presented at the 2023 ASCO Annual Meeting I and published in Journal of Clinical Oncology as Conference Abstract (JCO. 2023;41:e16148. doi: 10.1200/JCO.2023.41.16_suppl.e16148). Both anti-programmed death 1/ligand-1 (PD-1/L1) antibody + anti-vascular endothelial growth factor (VEGF) antibody (A + A) and anti-PD-1/L1 antibody + VEGF receptor (VEGFR)-targeted tyrosine kinase inhibitor (A + T) are effective first-line therapies for unresectable hepatocellular carcinoma. However, there lacks evidence from head-to-head comparisons between these two treatments. We conducted a network meta-analysis on the efficacy and safety of them. Methods: After a rigorous literature research, 6 phase III trials were identified for the final analysis. The endpoint was overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and incidence of treatment-related adverse events (TRAEs). Hazard ratio (HR) with 95% confidence intervals (CIs) for OS and PFS, odds ratio (OR) for ORR, and relative risk (RR) for TRAEs were calculated. Under the Bayesian framework, the meta-analysis was conducted using sorafenib as intermediate reference. Results: With the rank probability of 96%, A + A showed the greatest reduction in the risk of death, without significant difference from A + T (HR: 0.82, 95% CI: 0.65–1.04). A + T showed the greatest effect in prolonging PFS and improving ORR with the rank probability of 77%, but there were no statistical differences with A + A. A + A was safer than A + T in terms of all grade of TRAEs (RR: 0.91, 95% CI: 0.82–1.00) and particularly in those grade ≥3 (RR: 0.65, 95% CI: 0.54–0.77). Conclusions: A + A had the greatest probability of delivering the longest OS, while A + T was correlated with larger PFS benefits at the cost of a lower safety rate.},
author = {Zhou, Yiwen and Li, Jingjing and Ying, Jieer},
doi = {10.37349/etat.2024.00236},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {568--580},
title = {{Anti-PD-1 / L1 antibody plus anti-VEGF antibody vs . plus VEGFR- targeted TKI as first-line therapy for unresectable hepatocellular carcinoma : a network meta-analysis}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002236},
volume = {5},
year = {2024},
number = {3}
}